BUZZ-Tango因季度亏损额超出预期而股价下跌8月11日 - ** 药物研发公司Tango Therapeutics TNGX.O 股价下跌3.3%,报26.75美元
** 据LSEG数据显示,该公司报告第二季度每股亏损37美分 ,而分析师平均预期为每股亏损31美分
** TNGX报告称,截至2026年6月30日的三个月内未产生合作收入,原因是与吉利德 GILD.O 的合作关系及研发活动已终止
** 该公司2025年同期曾录得320万美元的合作收入
** 6月,TNGX表示,其药物vopimetostat与Revolution Medicines旗下 RVMD.O 的daraxonrasib联合用药,在12名曾接受过治疗的特定类型胰腺癌患者中,有11人的肿瘤缩小 (link)
** 计入本交易日涨幅在内,该股年初至今涨幅已超过三倍
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.